JRCT ID: jRCT2080225238
Registered date:19/06/2020
Basic Information
Recruitment status | completed |
---|---|
Health condition(s) or Problem(s) studied | |
Date of first enrollment | 10/07/2020 |
Target sample size | 2640 |
Countries of recruitment | Japan,Asia except Japan,North America,South America,Europe,Oceania,Africa |
Study type | Interventional |
Intervention(s) | investigational material(s) Generic name etc : INN of investigational material : Otilimab Therapeutic category code : 399 Agents affecting metabolism, n.e.c. Dosage and Administration for Investigational material : control material(s) Generic name etc : INN of investigational material : - Therapeutic category code : Dosage and Administration for Investigational material : |
Outcome(s)
Primary Outcome | safety |
---|---|
Secondary Outcome | efficacy |
Key inclusion & exclusion criteria
Age minimum | >= 18age old |
---|---|
Age maximum | Not applicable |
Gender | Both |
Include criteria | |
Exclude criteria |
Related Information
Primary Sponsor | |
---|---|
Secondary Sponsor | |
Source(s) of Monetary Support | |
Secondary ID(s) | NCT04333147,JapicCTI-205334 |
Contact
Public contact | |
Name | |
Address | 4-10-18, Takanawa, Minato-ku, Tokyo, Japan |
Telephone | - |
contRAst_Japan_JAPIC@iqvia.com | |
Affiliation | IQVIA Japan |
Scientific contact | |
Name | |
Address | 4-10-18, Takanawa, Minato-ku, Tokyo, Japan |
Telephone | - |
contRAst_Japan_JAPIC@iqvia.com | |
Affiliation | IQVIA Japan |